CAB7-3 

CAB7-3 is an orally active HBV capsid assembly modulator (CAM). CAB7-3 exhibits an exceptional antiviral efficacy reducing HBV DNA with an EC₅₀ = 70 nM, CC₅₀ = 32.3 μM in HepDES19 cells. CAB7-3 exhibits significant anti-HBV activity in HBV-integrated HepDES19 (EC₅₀ = 70 nM), HepAD38 (EC₅₀ = 1 nM) and HBV-infected HLCZ01 cells (EC₅₀ = 2 nM), respectively. CAB7-3 effectively reduces Hepatic HBV core protein levels and suppresses viral replication in vivo. CAB7-3 demonstrates a favorable drug-like and safety profile. CAB7-3 can be used for Hepatitis B Virus (HBV) research^[1].

CAB7-3 (0.001-1 μM，6 天) 在多种细胞模型中显示出抗病毒活性：在 HepAD38 细胞中，EC₅₀ = 1 nM，CC₅₀ = 26.54 μM，SI = 26540；在 HepDES19 细胞中，EC₅₀ = 7 nM，CC₅₀ = 32 μM，SI = 481；在 HBV 感染的 HLCZ01 细胞中，EC₅₀ = 2 nM，CC₅₀ = 30.73 μM，SI = 15365^[1]。
CAB7-3 (0.0003-1 μM，6 天) 在 HepAD38 和 HLCZ01 细胞中能够阻断新的 cccDNA 形成，同时不影响由已存在的 cccDNA 所产生的 HBsAg 分泌^[1]。
CAB7-3 (0.006-4 μM，3 天) 在 HepG2 细胞中能够诱导 HBV 核心蛋白降解并破坏衣壳组装^[1]。
CAB7-3 (1 μM，0-60 分钟) 在人肝微粒体中的代谢稳定性参数为：半衰期 (T^1/2) = 169 分钟、微粒体固有清除率 (CL^int(mic)) = 8.2 μL/min/mg、肝脏固有清除率 (CL^int(liver)) = 7.4 mL/min/kg、60 分钟后剩余量 = 78.0%^[1]。
CAB7-3 (10 μM) 在人原代肝细胞中不诱导 CYP3A4表达^[1]。
CAB7-3 (0.3-100 μM) 在表达 hERG 通道的 HEK293 细胞中表现出显著较低的 hERG 通道抑制率：在0.3、1、3、10、30 和 100 μM 浓度下的抑制率分别为 3.52%、14.59%、31.84%、61.05%、83.05% 和 94.76%^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CAB7-3 (口服给药，15 mg/kg，每日一次，持续 18 天) 在 HBV 携带小鼠模型中，通过抑制 HBV 衣壳组装，进而抑制含病毒 DNA 颗粒的分泌^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

656.33

C₂₈H₂₈BBrFN₅O₅S

3014372-17-6

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Jin Y, et al. Design, Synthesis, and Biological Evaluation of Highly Potent Boronic Acid (Boronate Ester)-Bearing Heteroaryldihydropyrimidine Derivatives as HBV Capsid Assembly Modulators. J Med Chem. 2025 Dec 25;68(24):25939-25960.  [Content Brief]